GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InfuSystems Holdings Inc (AMEX:INFU) » Definitions » Gross Profit

InfuSystems Holdings (InfuSystems Holdings) Gross Profit : $63.1 Mil (TTM As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is InfuSystems Holdings Gross Profit?

InfuSystems Holdings's gross profit for the three months ended in Dec. 2023 was $14.9 Mil. InfuSystems Holdings's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $63.1 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. InfuSystems Holdings's gross profit for the three months ended in Dec. 2023 was $14.9 Mil. InfuSystems Holdings's Revenue for the three months ended in Dec. 2023 was $31.8 Mil. Therefore, InfuSystems Holdings's Gross Margin % for the quarter that ended in Dec. 2023 was 46.84%.

InfuSystems Holdings had a gross margin of 46.84% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of InfuSystems Holdings was 71.22%. The lowest was 50.17%. And the median was 59.64%.

Warning Sign:

InfuSystems Holdings Inc gross margin has been in long-term decline. The average rate of decline per year is -2.8%.


InfuSystems Holdings Gross Profit Historical Data

The historical data trend for InfuSystems Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InfuSystems Holdings Gross Profit Chart

InfuSystems Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.88 58.76 58.54 60.56 63.11

InfuSystems Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.07 15.54 16.44 16.25 14.88

Competitive Comparison of InfuSystems Holdings's Gross Profit

For the Medical Instruments & Supplies subindustry, InfuSystems Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InfuSystems Holdings's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InfuSystems Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where InfuSystems Holdings's Gross Profit falls into.



InfuSystems Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

InfuSystems Holdings's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=125.785 - 62.676
=63.1

InfuSystems Holdings's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=31.771 - 16.89
=14.9

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $63.1 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

InfuSystems Holdings's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=14.9 / 31.771
=46.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


InfuSystems Holdings  (AMEX:INFU) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

InfuSystems Holdings had a gross margin of 46.84% for the quarter that ended in Dec. 2023 => Durable competitive advantage


InfuSystems Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of InfuSystems Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


InfuSystems Holdings (InfuSystems Holdings) Business Description

Traded in Other Exchanges
Address
3851 West Hamlin Road, Rochester Hills, MI, USA, 48309
InfuSystems Holdings Inc is a United States based healthcare service provider. It offers Infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from the locations in the United States and Canada. The company provides products and services to hospitals, oncology practices and chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The segments of the company are Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) services, of which key revenue is derived from the ITS segment.
Executives
Jerod Funke officer: EVP-Chief HR Officer 3851 WEST HAMLIN RD, ROCHESTER HILLS MI 48309
R. Rimmy Malhotra director C/O COMMAND CENTER, INC., 3609 S WADSWORTH BLVD., SUITE 250, LAKEWOOD CO 80235
Gregg Owen Lehman director 309 HADDON COURT, FRANKLIN X1 37067
Richard Dilorio officer: Executive Vice President 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Barry G Steele officer: Executive VP and CFO 500 TOWN CENTER DR., SUITE 200, DEARBORN MI 48126
Carrie Lachance officer: Executive VP and COO 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Christopher R. Sansone director C/O SANSONE ADVISORS, LLC, 151 BODMAN PLACE, SUITE 100, RED BANK NJ 07701
Addam Chupa officer: Executive VP and CIO 3851 WEST HAMLIN ROAD, ROCHESTER HILLS MI 48309
Kevin Whitman officer: VP and Corporate Controller 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Thomas Mark Ruiz officer: VP of Sales and Marketing 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Boyd Ralph F Jr director
Paul Andrew Gendron director 740 BANDIT TRAIL, KELLER TX 76248
Jeannine Sheehan officer: Chief Administrative Officer 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Blueline Capital Partners Ii, L.p. director 3480 BUSKIRK AVENUE, SUITE 214, PLEASANT HILL CA 94523
Meridian Tsv Ii, Lp 10 percent owner 405 WEED STREET, NEW CANAAN CT 06840